Yehuda G. Assaraf

Overview

Best Publications

• Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies

  Wen Li;Han Zhang;Yehuda G. Assaraf;Kun Zhao

  624
  Citations

• Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.

  Jan Hendrik Hooijberg;Henk J. Broxterman;Marcel Kool;Yehuda G. Assaraf

  596
  Citations

• Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein

  Ruud Oerlemans;Niels E. Franke;Yehuda G. Assaraf;Jacqueline Cloos

  559
  Citations

• Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance

  Alina Shapira;Yoav D. Livney;Henk J. Broxterman;Yehuda G. Assaraf

  546
  Citations

• Modulating ROS to overcome multidrug resistance in cancer.

  Qingbin Cui;Jing-Quan Wang;Yehuda G. Assaraf;Liang Ren

  527
  Citations

• Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance.

  Nitzan Gonen;Yehuda G. Assaraf

  485
  Citations

• Molecular basis of antifolate resistance.

  Yehuda G. Assaraf

  441
  Citations

• The multi-factorial nature of clinical multidrug resistance in cancer.

  Yehuda G. Assaraf;Anamaria Brozovic;Ana Cristina Gonçalves;Dana Jurkovicova

  418
  Citations

• Lysosomes as mediators of drug resistance in cancer.

  Benny Zhitomirsky;Yehuda G. Assaraf

  413
  Citations

• The folate receptor as a rational therapeutic target for personalized cancer treatment

  Yehuda G. Assaraf;Christopher P. Leamon;Joseph A. Reddy

  376
  Citations

• Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance

  Kristy J. Gotink;Henk J. Broxterman;Mariette Labots;Richard R. de Haas

  358
  Citations

• Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.

  Maya Bar-Zeev;Yoav D. Livney;Yehuda G. Assaraf

  284
  Citations

• The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.

  Yehuda G. Assaraf

  276
  Citations

• The role of passive transbilayer drug movement in multidrug resistance and its modulation

  Gera D. Eytan;Ronit Regev;Galit Oren;Yehuda G. Assaraf

  243
  Citations

• Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.

  Silpa Narayanan;Chao-Yun Cai;Yehuda G. Assaraf;Hui-Qin Guo

  239
  Citations

• Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.

  Sophie Taylor;Enrico Pierluigi Spugnini;Yehuda G. Assaraf;Tommaso Azzarito

  237
  Citations

• Potentiation of Anticancer-Drug Cytotoxicity by Multidrug-Resistance Chemosensitizers Involves Alterationsin Membrane Fluidity Leading to Increased Membrane Permeability

  Stavit Drori;Gera D. Eytan;Yehuda G. Assaraf

  235
  Citations

• Membrane fluidization by ether, other anesthetics, and certain agents abolishes P‐glycoprotein ATPase activity and modulates efflux from multidrug‐resistant cells

  Ronit Regev;Yehuda G. Assaraf;Gera D. Eytan

  219
  Citations

• Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance

  Benny Zhitomirsky;Yehuda G. Assaraf

  216
  Citations

• Impaired bortezomib binding to mutant beta 5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.

  N E Franke;D Niewerth;Y G Assaraf;J van Meerloo

  209
  Citations